Randomized placebo-controlled phase II trial of autologous mesenchymal stem cells in multiple sclerosis.

PLoS One · 2014 · PMC4250058 · PMID 25436769

Europe PMC DOI

hedged sentences

0.0650

closest p · 1.3× alpha

0.0660

boldest claim

The sentences

showed a trendp = 0.065so close (0.05 < p ≤ 0.1)

Additionally, the sensitivity analysis without the LOCF strategy also showed a trend to lower accumulate number of GEL at 6 months in the MSCs group (1.53, 95% CI 0.53–4.42 vs 6.15, 95% CI 2.19–17.28, p = 0.065).

also in 53,322 other papers

a significant trendp = 0.066so close (0.05 < p ≤ 0.1)

The analysis of the cumulative number of GEL between the first and the second period of treatment showed a significant trend to lower mean number of GEL in the second period suggesting a potential carryover effect of MSCs administration (13.33±20.5 vs 9.78±20.02, p = 0.066).

also in 9,775 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.